Simple Summary Pancreatic cancer is one of the most lethal cancers. It is a difficult cancer to
treat, and the complexity surrounding the pancreatic tumour is one of the contributing factors …

Simple Summary This review summarizes recent advances in the nuclear medicine
theranostic approach. It covers the repurposing of historical radiotracers for new indications …

Pancreatic cancer is a highly lethal solid malignancy with limited treatment options. Chimeric
antigen receptor T (CAR-T) cell therapy has been successfully applied to treat hematological …

Purpose Rucaparib, an FDA-approved PARP inhibitor, is used as a single agent in
maintenance therapy to provide promising treatment efficacy with an acceptable safety …

Simple Summary Patients diagnosed with pancreatic cancer have a poor prognosis at time
of diagnosis, with a 5-year survival rate of merely 10%. The only treatment with curative …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis,
mainly due to difficulty in early detection of the disease by current imaging modalities. In this …

Abstract Background Sodium glucose transporters (SGLTs) play vital roles in glucose uptake
in many solid cancers, including pancreatic cancer (PC). However, their expression profile in …

On stage, and in real life, timing is critical for success. Theranostic cancer care epitomizes
the central role of timing in the evolution of efficacious molecular targeted radioligand …

Pancreatic ductal adenocarcinoma (PDAC) is insidious and highly malignant with extremely
poor prognosis and drug resistance to current chemotherapies. Therefore, there is a critical …

Simple Summary Pancreatic adenocarcinoma is a leading cause of cancer related deaths
worldwide. Since surgical treatment involves serious risk and morbidity, guiding patients …